FEMASYS INC Stock Price, News & Analysis

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, will participate in the 2022 Virtual Growth Conference from March 28-30. CEO Kathy Lee-Sepsick will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 from 3:00 pm to 4:30 pm ET. The conference will discuss innovations in women's health, highlighting Femasys's ongoing development of minimally invasive technologies, including FemBloc® and FemaSeed® for permanent birth control and infertility treatment respectively. For more details, registration is available online.

Femasys Inc. (NASDAQ: FEMY) reported its 2021 financial results, showcasing a revenue increase of 13.7% to $1.18 million from FemVue® sales. R&D expenses slightly decreased by 1.1% to $4.08 million, while G&A expenses surged by 67.5% to $4.26 million due to increased professional costs. The net loss was $7.54 million, equating to $1.12 per share, a rise from the previous year's loss of $6.91 million. The company anticipates significant clinical advancements, including the upcoming launch of FemCerv® and completion of the FemBloc study enrollment.

Femasys Inc. (NASDAQ: FEMY) has appointed Dov Elefant as Chief Financial Officer, effective February 28, 2022. With 25 years of experience in financial management in the biotech sector, Elefant's expertise includes fundraising and mergers and acquisitions. He aims to enhance Femasys' growth and strategic direction in women's health technologies, including their lead products, FemBloc® and FemaSeed®. Additionally, an inducement option has been granted for 100,000 shares to Elefant, vesting over four years. This leadership change is expected to strengthen the company's financial strategy.

Femasys Inc. (NASDAQ: FEMY) has appointed Wendy Perrow to its board of directors, bringing extensive experience in fundraising and corporate strategy. Perrow's background includes leadership roles in several biotechnology companies, notably raising $31 million for Alba Therapeutics. This announcement coincides with the resignation of William Witte, who served since 2017. The leadership change comes at a crucial time as Femasys prepares for pivotal trials for its product candidates FemBloc and FemaSeed. Perrow aims to leverage her expertise to enhance the company's growth in women's reproductive health.

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, announced its participation in two upcoming virtual conferences. The LifeSci Partners 11th Annual Corporate Access Event will feature CEO Kathy Lee-Sepsick on January 6, 2022, discussing gender equality in life sciences. Additionally, Femasys will present at the H.C. Wainwright BioConnect Conference, with a recording available from January 10, 2022. Femasys develops minimally invasive technologies, including FemBloc® and FemaSeed® for reproductive health needs.

Femasys Inc. (NASDAQ: FEMY) has received investigational device exemption approval for its pivotal LOCAL trial involving FemaSeed®, aimed at improving women's reproductive health. The company reported third-quarter 2021 financial results, highlighting a net loss of $(2.26) million, with revenue from FemVue® declining by 13.9% year-over-year to $269,581. However, sales increased by 22.2% for the nine months ended September 30, 2021, totaling $925,362. The company also announced its addition to the Russell Microcap® Index and the appointment of a new chief medical officer.

Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present at The MedTech Conference on September 30, 2021, in Minneapolis. She will be part of a panel discussion titled “Early-Stage Medtech and Going Public,” scheduled from 10:00 to 10:35 a.m. ET. The conference runs from September 21 to 30, 2021, and focuses on advancements in medical technology. Femasys aims to address women’s health needs with innovative products, including FemBloc® and FemaSeed™. The company is committed to developing minimally invasive solutions for reproductive health.

Femasys Inc. (NASDAQ: FEMY) announced its inclusion in the Russell Microcap® Index, effective September 20, 2021. This recognition enhances the company's visibility in the global investment community and is expected to benefit stockholders. The CEO, Kathy Lee-Sepsick, highlighted the significance of this milestone following their IPO in June. The company aims to advance its product candidates, including FemBloc® and FemaSeed™, which target women’s healthcare needs through innovative, minimally invasive technologies. Membership in the index will last for one year.

Femasys Inc. (NASDAQ: FEMY) has appointed Dr. Edward G. Evantash as its new Chief Medical Officer, bringing over 20 years of experience in medical affairs, particularly in women's healthcare. Dr. Evantash, previously with Alydia Health and Hologic, will lead Femasys' clinical development programs, including advancing the late-stage candidates, FemaSeed™ and FemBloc®. His expertise aims to address unmet needs in reproductive health and enhance Femasys' strategic initiatives, particularly in clinical trial execution and FDA submissions.